ILMN

Illumina, Inc.

Next est. report 2026-10-29 · AMC

Cycle Long '24: Health & Life Sciences Genomics '25: Sequencing Hardware MedTech Long '25: Diagnostic Platforms MedTech Long '26: Diagnostics & Early Detection MedTech Long '26: Life Science Tools & Bioprocessing

Loading…

Loading chart…

Overview

Illumina, Inc. provides genetic and genomic analysis tools, including sequencing instruments like NovaSeq X and consumables, for research and clinical use. Its

Illumina, Inc. provides genetic and genomic analysis tools, including sequencing instruments like NovaSeq X and consumables, for research and clinical use. Its offerings support life sciences, cancer diagnostics, and reproductive health. Clinical applications drive approximately 65% of sequencing consumables revenue. The company also offers multi-omics solutions and AI-enabled drug discovery services, serving genomic research facilities, medical centers, and biotech firms globally.

Search Keywords Brand Product

NovaSeq X
StrataMap Spatial
SomaScan
SomaSeq
BioInsight
Billion Cell Atlas
MiSeq i100
TruPath
genomic sequencing
next-generation sequencing
NGS
multi-omics
spatial biology
proteomics
AI drug discovery
clinical diagnostics
rare disease sequencing
oncology sequencing
MRD testing

Search Keywords Event Phrases

Illumina Q2 2026 earnings
Illumina 2026 guidance

What They Do (Plain English & Analogies): Illumina is like a high-tech detective agency for your genes. They make the specialized tools and chemicals that scientists and doctors use to "read" the entire genetic instruction book (DNA) of a person, animal, or plant. This helps them understand what makes us unique, what causes diseases like cancer, how to develop new medicines, or even how to improve crops. They provide the "microscopes" (sequencing machines like the NovaSeq X) and the "slides and stains" (reagents and arrays) to uncover these genetic secrets. They also offer services to help analyze the massive amounts of data generated, and are now expanding into tools that look at other biological information beyond just DNA, like proteins and how cells are organized in tissues, to get an even fuller picture of biology.
Very Brief History: Illumina, Inc. was founded in April 1998 and is headquartered in San Diego, California. Since its inception, the company has focused on developing and commercializing integrated systems for genetic analysis, evolving into a global leader in sequencing and array technologies. Key milestones include the continuous innovation of its sequencing platforms, such as the NovaSeq X, and strategic expansions into multi-omics capabilities through acquisitions like SomaLogic and internal developments like BioInsight.
"Street Stereotype": Illumina is generally perceived as the dominant incumbent in the next-generation sequencing (NGS) hardware and consumables market. It's seen as the foundational technology provider for much of the global genomics research and clinical testing infrastructure, particularly for liquid biopsy and multi-omics. While facing increasing competition, especially in lower-cost sequencing, its NovaSeq X platform is viewed as a key driver for future growth and maintaining its market leadership.
Subsidiaries On Linked In*: Illumina GmbH — German subsidiary mentioned in a patent case
Customer Sectors & Example Clients: Illumina's customers span a wide range of sectors including: genomic research facilities, universities and academic institutions, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, businesses focused on consumer genomics, and agriculture (agrigenomics). Example clients (educated guesses based on industry leaders and common users of NGS technology): Broad Institute, Mayo Clinic, Quest Diagnostics, LabCorp, Amgen, 23andMe.
New Customers / Segments They'Re Targeting: Illumina is actively targeting new customer segments by expanding its platform value through new workflows and multi-omics capabilities. This includes pharmaceutical customers for AI-enabled drug discovery through its BioInsight platform and Billion Cell Atlas program, which provides high-quality multi-omics data sets. They are also expanding their reach in spatial biology with the StrataMap Spatial workflow, allowing researchers to study tissue biology in new ways. Furthermore, their SomaScan and SomaSeq offerings are generating interest in connecting proteomics and genomic insights, broadening their support for research and clinical markets.
Supply Chain And Sourcing Geographies: Illumina's supply chain involves sourcing critical components, particularly electronic components and memory, for its instruments. The company has experienced inflationary pressures related to freight costs and higher costs for these electronic components. In Q2 2026, Illumina made significant supply investments and secured additional inventory for critical components for the next several quarters to mitigate risks from price movements. While specific sourcing geographies are not detailed, the mention of electronic components suggests reliance on a global electronics supply chain, likely including East Asia. Illumina's instruments utilize a different, less expensive architecture than GPU-based systems.
Sales Geographies And Expansion Plans: Illumina sells its products directly to clients across North America (with strong growth in the U.S.-Canada region), Europe, Latin America, and the Asia-Pacific. They also utilize life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. The company's reporting segments include "Rest of World organic growth" and considers the impact from its "Greater China region," confirming active sales in these areas. Management did not explicitly disclose plans to expand sales into entirely new geographies, but rather emphasized expanding market penetration within existing regions, especially in clinical applications.
How Key Themes May Help/Hurt: Illumina is positioned to benefit significantly from the "MedTech Long '26: Life Science Tools & Bioprocessing" theme. The theme's bullish drivers, such as the sustained recovery in biotech venture capital funding and the increasing demand for complex biologics, directly fuel R&D spending and clinical development, which in turn drives demand for Illumina's sequencing tools and multi-omics solutions. The AI integration accelerating drug discovery (Bull2) is a direct tailwind for Illumina's BioInsight and Billion Cell Atlas initiatives. While the theme also notes potential bear points like geopolitical tensions and slow translation of funding into spending, Illumina's strong clinical market momentum and diversified offerings help mitigate some of these risks. The company's focus on expanding clinical applications and multi-omics capabilities aligns well with the broader industry's move towards more comprehensive biological insights, which is a core aspect of the theme.

3 Main Long-Term Bull Details

Dominance and Expansion in Clinical Genomics: Illumina is experiencing sustained and robust growth in clinical markets, with clinical consumables growing mid-teens year-over-year and comprising approximately 65% of sequencing consumables revenue. The NovaSeq X platform continues to see strong demand and placements, especially in clinical settings, expanding the installed base and driving long-term consumables revenue for applications like oncology (MRD, therapy selection), rare diseases, and NIPT screening.
Continuous Innovation and Expanding Multi-omics Platform Value: Illumina is committed to continuous innovation, evidenced by the launch of the whole genome MRD research workflow and the StrataMap Spatial sequencing-based spatial workflow. The SomaLogic acquisition has brought SomaScan and SomaSeq offerings, and the BioInsight platform, including the Billion Cell Atlas, is leveraging AI for drug discovery. These innovations expand the utility of Illumina's ecosystem, ensuring its relevance and driving future demand by offering more comprehensive biological insights.
Strong Financial Trajectory and Operational Discipline: Despite a dynamic macro environment, Illumina delivered a strong Q2 2026, exceeding revenue and EPS guidance, and subsequently raised its full-year 2026 outlook for revenue growth and profitability. The company is making progress towards its 2027 targets of high single-digit revenue growth and continued margin expansion, reflecting disciplined execution and operational leverage, including managing inflationary pressures.

3 Main Long-Term Bear Details

Cautious Research and Academic Market Demand: Demand in research and academic markets remains cautious due to funding uncertainty, with sequencing consumables in this segment experiencing declines. While some signs of improvement were noted late in Q2, it's too early to call a recovery, posing a continued headwind to a significant portion of Illumina's business and potentially impacting future innovation adoption.
Competitive Pressures and Pricing Dynamics: The competitive landscape continues to evolve, with new entrants and technologies. While Illumina expresses confidence, the need to offer volume discounts on NovaSeq X placements and the cautious stance on future flow cell pricing suggest potential future pricing pressures and increased competition for market share, which could impact margins.
Supply Chain and Inflationary Pressures: Illumina continues to face inflationary pressures related to freight costs and higher costs of electronic components and memory. While the company has taken mitigating actions by securing supply for several quarters, persistent supply chain issues or unmanaged cost increases could impact instrument production, gross margins, and overall profitability, despite efforts to absorb these costs.

Competitors And Differentiation: Illumina's competitors include other sequencing hardware and consumables providers. While the transcript doesn't name specific direct competitors in Q2 2026, previous context mentions Element Biosciences and 10x Genomics. Illumina differentiates itself by: Dominant Market Position: Maintaining a large installed base and deep relationships with leading clinical customers. Comprehensive Ecosystem: Offering end-to-end workflows, from sample preparation to data analysis, across core sequencing and multi-omics. Innovation: Continuously developing new platforms (NovaSeq X roadmap with new flow cells), workflows (whole genome MRD research workflow, StrataMap Spatial), and multi-omics capabilities (SomaScan, SomaSeq, BioInsight, Billion Cell Atlas). Quality and Cost-Effectiveness: Striving to deliver the highest quality insights for the lowest end-to-end cost, making their technology accessible for expanding clinical applications. Broadest Range of Instruments: Offering instruments from high-throughput (NovaSeq X) to low-throughput (MiSeq i100) to cater to diverse customer needs and project scales.
Recent Performance & What The Market'S Focused On: Illumina had a strong first half of 2026, with Q2 revenue growing 9.5% year-over-year to $1.16 billion, and non-GAAP EPS increasing 10% to $1.31, both exceeding guidance. The company raised its full-year 2026 guidance for revenue growth (Rest of world organic growth greater than 5%) and profitability (EPS $5.30-$5.40). The market is primarily focused on the continued robust demand and placements of the NovaSeq X instrument (over 95 units in Q2), especially in clinical markets, which are driving strong consumables growth (mid-teens growth expected for clinical consumables). Investors are also tracking the progress of multi-omics initiatives like StrataMap Spatial and the Billion Cell Atlas, and the recovery in research and academic markets, which remain cautious. The company's ability to manage inflationary costs while expanding margins is also a key focus.

Revenue Segments And Estimated Mix: Sequencing Consumables — Mix: ~66.8%; Source: Q2 2026 transcript (775M / 1160M); Trend: Up 5% YoY (reported and organic Rest of World basis); Clinical grew 15% ex-China; Research and applied declined 7% Rest of World.
Sequencing Instruments — Mix: ~10.8%; Source: Q2 2026 transcript (125M / 1160M); Trend: Up 31% YoY (reported and organic Rest of World basis); Driven by NovaSeq X and MiSeq i100 sales.
Sequencing Service and Other — Mix: ~13.3%; Source: Q2 2026 transcript (154M / 1160M); Trend: Up 14% YoY (reported and organic Rest of World basis); Higher data revenue from Billion Cell Atlas.
Microarrays and Other — Mix: ~9.1%; Source: Q2 2026 transcript (105M / 1160M); Trend: Up 21% reported (includes SomaLogic revenue); Declined 4% on a Rest of World organic basis.
Product Brands: NovaSeq X Series
NovaSeq 6000 System
MiSeq i100 Series
MiSeq System
NextSeq 1000 & 2000 Systems
NextSeq 550 System
iSeq 100 System
TruPath
BioInsight
Billion Cell Atlas
5-Base Solution
DRAGEN Secondary Analysis
Illumina Connected Analytics
Infinium (microarray technology)
iScan System
fireflyGO
Trusight Oncology
Illumina DNA Prep
Pillar oncoReveal
TruSight Panels
AmpliSeq for Illumina
XLEAP-SBS chemistry
StrataMap Spatial
SomaScan
SomaSeq

Bull / Bear Details

Illumina maintains a bullish outlook, driven by exceptional Q2 2026 performance with revenue growing at its fastest rate, fueled by robust clinical market deman

Thesis

Illumina maintains a bullish outlook, driven by exceptional Q2 2026 performance with revenue growing at its fastest rate, fueled by robust clinical market demand and over 95 NovaSeq X placements. Strategic expansion into multi-omics, including StrataMap Spatial and BioInsight's Billion Cell Atlas, enhances platform value and future growth. Despite persistent caution in research markets and inflationary cost pressures, raised 2026 guidance and commitment to high single-digit 2027 revenue growth reinforce its sustainable trajectory. (Updated: 2026-08-07)

Bull case

Illumina is experiencing robust demand in clinical markets, with sequencing consumables (ex-China) growing 15% year-over-year in Q2 2026, comprising approximately 65% of consumables revenue. Over 95 NovaSeq X placements in the quarter, driven by clinical customers expanding capacity for sequencing-based diagnostics, reinforce a strong installed base that will drive sustained consumables pull-through and long-term growth.
Illumina's innovation pipeline is expanding platform value through multi-omics capabilities and AI-enabled drug discovery. Recent launches include the StrataMap Spatial workflow and a whole genome MRD research workflow. Sustained proteomics momentum from SomaLogic's SomaScan/SomaSeq and BioInsight's Billion Cell Atlas, which has secured six pharma partners and is generating revenue, further broadens customer applications and future growth drivers.
Illumina delivered a strong Q2 2026, with revenue growing at its fastest rate and exceeding guidance, leading to a raised full-year 2026 outlook for Rest of World organic revenue growth (greater than 5%) and EPS ($5.30-$5.40). The company remains committed to its 2027 target of high single-digit revenue growth, reflecting disciplined execution, operational leverage, and a strong setup for continued consumable growth.

Bear case

Demand in research and academic markets remains cautious due to persistent funding uncertainty, leading to a 7% decline in Rest of World research and applied sequencing consumables in Q2 2026. While some late-quarter improvements were noted, it is too early to call a recovery, posing a continued headwind to a significant portion of Illumina's business and potentially impacting future innovation adoption.
Near-term operating margins face pressure from inflationary costs, as Illumina absorbed higher freight and memory costs in Q2 2026. Additionally, slower clinical consumables growth in the Europe, Middle East, and Latin America region due to regional dynamics, and a muted mid-throughput instrument market due to the macro environment, could impact overall profitability and growth rates in certain segments.
The competitive landscape continues to evolve, with ongoing discussions around aggressive pricing from new entrants and the need for volume discounts on NovaSeq X placements. While Illumina expresses confidence in its value proposition and market leadership, potential future pricing pressures and increased competition for market share, particularly as new technologies emerge, remain a long-term risk that could impact revenue growth and margin expansion.

Bull / Bear Case

Bear Case: Demand in research and academic markets remains cautious due to persistent funding uncertainty, leading to a 7% decline in Rest of World research and applied sequencing consumables in Q2 2026. While some late-quarter improvements were noted, a full recovery is not yet evident, posing a continued headwind to a significant portion of Illumina's business. Near-term operating margins face pressure from inflationary costs, as Illumina absorbed higher freight and memory costs in Q2 2026. Additionally, slower clinical consumables growth in the Europe, Middle East, and Latin America region due to regional dynamics, and a muted mid-throughput instrument market due to the macro environment, could impact overall profitability and growth rates. The competitive landscape continues to evolve, with potential future pricing pressures and increased competition for market share remaining a long-term risk.
Bull Case: Illumina is experiencing robust demand in clinical markets, with sequencing consumables (ex-China) growing 15% year-over-year in Q2 2026, comprising approximately 65% of consumables revenue. Over 95 NovaSeq X placements in the quarter, driven by clinical customers expanding capacity for sequencing-based diagnostics, reinforce a strong installed base that will drive sustained consumables pull-through and long-term growth. The innovation pipeline is expanding platform value through multi-omics capabilities and AI-enabled drug discovery, with recent launches like StrataMap Spatial and the BioInsight Billion Cell Atlas gaining traction and generating revenue. Illumina delivered a strong Q2 2026, exceeding revenue and EPS guidance, leading to a raised full-year 2026 outlook for Rest of World organic revenue growth (greater than 5%) and EPS ($5.30-$5.40), reinforcing its commitment to high single-digit revenue growth in 2027.
More Compelling & Why: Bear. Despite strong Q2 performance, Illumina appears significantly overvalued. Multiple intrinsic value analyses suggest the stock is overvalued by 22% to 46.8% at its current price, and its P/E ratio (mid-30s) remains elevated compared to the sector median of 26.2x, especially given its mid-single-digit organic revenue growth guidance. The strongest argument for the bear case is this persistent overvaluation in the face of ongoing headwinds in research markets and inflationary pressures. My view would flip if the stock price corrected significantly (e.g., a 20-30% decline) or if the company demonstrated a clear path to sustained double-digit organic revenue growth that would justify its premium valuation.

Key Factors5 rows

Key Factor	Why It Matters	What To Watch	What It Signals	Where/How To Track	Free Alt Data	Paid Alt Data
Adoption of StrataMap Spatial and Multi-omics Portfolio	Expanding into multi-omics capabilities like spatial biology and proteomics broadens Illumina's addressable market and provides new revenue streams, enhancing the value of its ecosystem and supporting long-term growth.	Commentary on initial customer feedback, order indications, and revenue contribution from StrataMap Spatial and other new multi-omics offerings (e.g., SomaScan, SomaSeq, Billion Cell Atlas) in Q3 and Q4 2026.	Bullish: Management reports strong initial customer adoption, significant order pipeline, or quantifiable revenue contribution (e.g., exceeding $10M) from StrataMap Spatial and other multi-omics products in Q3 2026. Bullish: Continued growth in BioInsight's Billion Cell Atlas program (e.g., adding more than 3 new partners per quarter, significant revenue contribution).	Illumina's Q3 and Q4 2026 earnings calls and press releases (Q3 earnings expected October 29, 2026). Industry conferences.	Scientific publications citing StrataMap Spatial or SomaScan/SomaSeq. Company webinars/presentations on new workflows.	AlphaSense/Sentieo: Mentions of 'StrataMap Spatial' or 'SomaScan' in competitor earnings calls or industry reports.
Clinical Sequencing Consumables Revenue Growth (ex-China)	This segment is a primary growth driver, making up approximately 65% of consumables revenue, reflecting increasing adoption of sequencing-based diagnostics and more data-intensive applications. Continued strong growth here validates Illumina's strategy in high-value clinical markets.	Rest of World organic clinical sequencing consumables revenue growth rate in Q3 and Q4 2026. Management expects mid-teens growth for the full year 2026.	Bullish: Clinical sequencing consumables (ex-China) growth remains at or above mid-teens year-over-year in Q3 2026. Bearish: Clinical sequencing consumables (ex-China) growth falls below 10% year-over-year in Q3 2026.	Illumina's Q3 and Q4 2026 earnings calls and press releases (Q3 earnings expected October 29, 2026).	Industry reports on NGS adoption in clinical diagnostics.	IQVIA: Clinical sequencing test volumes for key applications (e.g., oncology, NIPT).
Research & Academic Market Demand Recovery	While clinical markets are strong, research and academic customers are an important source of innovation and help drive clinical adoption over time. A recovery in this segment would provide an upside to overall revenue growth.	Year-over-year growth rate for Research and Applied sequencing consumables (Rest of World) in Q3 and Q4 2026. Management expects mid to high single-digit declines for 2026, but noted signs of improvement late in Q2.	Bullish: Research and Applied sequencing consumables (Rest of World) decline moderates to less than -5% year-over-year in Q3 2026, or turns positive. Bearish: Research and Applied sequencing consumables (Rest of World) decline remains at or worsens from -7% year-over-year in Q3 2026.	Illumina's Q3 and Q4 2026 earnings calls and press releases (Q3 earnings expected October 29, 2026). NIH funding announcements.	USASpending.gov: Government research grant awards for genomics. Google Trends: 'genomics research funding' or 'NGS academic labs'.	PitchBook-NVCA Venture Monitor: Biotech R&D funding trends.
NovaSeq X Clinical Volume Transition & Pull-Through	Successful transition of clinical volumes to NovaSeq X ensures high utilization of the new platform, driving sustained, high-margin consumables pull-through and solidifying Illumina's leadership in clinical genomics.	Percentage of clinical volume transitioned to NovaSeq X in Q3 and Q4 2026. Management expects 80-85% clinical volume conversion by end of 2026. Also, monitor NovaSeq X pull-through (currently above $1.3 million).	Bullish: Clinical volume on NovaSeq X reaches or exceeds 80% by Q3 2026, or pull-through remains at or above $1.3 million per instrument. Bearish: Clinical volume transition to NovaSeq X slows significantly (e.g., less than 79% by Q3 2026), or NovaSeq X pull-through declines below $1.2 million.	Illumina's Q3 and Q4 2026 earnings calls and press releases (Q3 earnings expected October 29, 2026).	N/A	Expert network calls with Illumina customers on NovaSeq X utilization.
NovaSeq X Instrument Placements	High NovaSeq X placements indicate strong customer adoption of Illumina's flagship platform, crucial for driving future, high-margin consumables revenue and signaling market leadership and expansion into clinical workflows.	Number of NovaSeq X units placed in Q3 and Q4 2026. Management expects elevated placements to continue in H2 2026, with some moderation in year-over-year growth rates.	Bullish: NovaSeq X placements in Q3 2026 remain at or above 90 units. Bearish: NovaSeq X placements fall significantly below 80 units in Q3 2026.	Illumina's Q3 and Q4 2026 earnings calls and press releases (Q3 earnings expected October 29, 2026).	Google Trends: 'NovaSeq X' search volume. Industry news sites covering genomics and sequencing.	Thinknum: Illumina job postings for manufacturing/supply chain roles (proxy for production scaling).

Key Reported Metrics, Reratings Triggers & Results3 rows

As a key bottom-line metric, Non-GAAP Diluted EPS reflects Illumina's overall profitability and operational efficiency. Strong EPS growth indicates effective co

Upcoming print · 2026-10-29

Key reported metrics
Metric	Last period	Why it matters
Non-GAAP Diluted EPS	$1.31 (10% y/y growth)	As a key bottom-line metric, Non-GAAP Diluted EPS reflects Illumina's overall profitability and operational efficiency. Strong EPS growth indicates effective cost management and leverage from revenue growth, directly impacting shareholder value.
Sequencing Instruments Revenue	15% y/y growth	Strong instrument placements, particularly of NovaSeq X, are crucial for expanding the installed base, which directly drives future, high-margin consumables revenue and signals market leadership.
Clinical Sequencing Consumables Revenue (ex-China)	15% y/y growth	This segment is the primary growth driver, reflecting increasing adoption of sequencing-based diagnostics and more data-intensive applications. Sustained growth validates Illumina's strategy in high-value clinical markets.

Last reported · 2026-07-30

Key reported metrics			Rerating thresholds			Earnings results
Metric	Last period	Why it matters	What's needed for rerating	Rerating context	Earnings date	Actual reported	Hit target?	Notes
Non-GAAP Diluted EPS	19%	As a key bottom-line metric, Non-GAAP Diluted EPS reflects Illumina's overall profitability and operational efficiency. Strong EPS growth indicates effective cost management and leverage from revenue growth, directly impacting shareholder value.	For the stock to rerate higher, Illumina's Non-GAAP Diluted EPS for Q2 2026 needs to exceed its guidance range of $1.20 to $1.25, ideally hitting $1.28 or higher, and the company should either raise or reaffirm the high end of its full-year 2026 guidance of $5.15 to $5.30.	Exceeding EPS expectations would confirm robust clinical market momentum and NovaSeq X adoption, demonstrating strong operational execution and mitigating concerns about research market softness and competitive pressures. This performance would justify a higher valuation multiple and reinforce investor confidence in Illumina's path to sustainable double-digit EPS growth.	2026-07-30	$1.31 (10% y/y growth)	Yes	Illumina's Non-GAAP Diluted EPS of $1.31 significantly exceeded its guidance range of $1.20 to $1.25 and the ideal target of $1.28. Furthermore, the company raised its full-year 2026 diluted EPS guidance to $5.30-$5.40, an increase of $0.12 at the midpoint, and above the prior high end of $5.30. This strong performance and raised outlook confirm robust operational execution and reinforce investor confidence.
NovaSeq X Placements	33.3%	High NovaSeq X placements indicate strong customer adoption of Illumina's flagship platform, which is crucial for driving future, high-margin consumables revenue. It signals market leadership and expansion into clinical workflows.	NovaSeq X Placements (representing the percentage of clinical volume transitioned to NovaSeq X) needs to reach 45-50% or higher in Q2 2026, demonstrating significant acceleration towards the 80-85% year-end target. Additionally, NovaSeq X instrument placements should exceed 80 units in Q2.	Hitting this threshold demonstrates accelerated adoption of Illumina's flagship NovaSeq X platform, crucial for driving future high-margin consumables revenue and confirming market leadership. It signals successful scaling of supply and strong progress towards the 80-85% clinical volume transition target by year-end, validating the company's growth strategy and competitive position.	2026-07-30	Over 95 units placed; 78% of clinical volume transitioned to NovaSeq X	Yes	Illumina exceeded both components of the NovaSeq X Placements rerating trigger. The company placed more than 95 NovaSeq X instruments in Q2, well above the 80-unit threshold. Additionally, approximately 78% of clinical volume has now transitioned to the NovaSeq X platform, significantly surpassing the 45-50% target and demonstrating strong progress towards the year-end goal of 80-85% conversion. This indicates robust demand and successful adoption of the flagship platform, which is expected to drive future consumables revenue.
Clinical Sequencing Consumables Revenue (ex China)	20%	This segment is a primary growth driver, making up over 65% of consumables revenue, reflecting increasing adoption of sequencing-based diagnostics and more data-intensive applications. Continued strong growth here validates Illumina's strategy in high-value clinical markets.	For Illumina (ILMN) to rerate higher, the Clinical Sequencing Consumables Revenue (ex China) metric needs to maintain or exceed its current 20% year-over-year growth rate in Q2 2026. This would align with recent analyst upgrades and their bullish sentiment, which anticipates another quarter near 20% growth to justify higher price targets.	This metric is a primary growth driver, reflecting increasing adoption of sequencing-based diagnostics and robust NovaSeq X utilization. Sustained growth at or above 20% validates Illumina's strategy in high-value clinical markets, justifying a premium valuation and confirming the bullish investment thesis.	2026-07-30	15% y/y growth	No	Clinical sequencing consumables revenue (ex-China) grew 15% year-over-year, falling short of the 20% rerating trigger. While the U.S.-Canada region continued to grow above 20%, slower growth in Europe, Middle East, and Latin America, attributed to near-term regional dynamics, impacted the overall clinical growth rate. Despite this, management raised the full-year outlook for clinical markets towards the high end of their prior guide, now expecting mid-teens growth for the year, indicating continued confidence in the segment's underlying strength.

Key Questions

Can Illumina sustain elevated NovaSeq X instrument placements in the second half of 2026, and will the expanding installed base translate into the anticipated a

Can Illumina sustain elevated NovaSeq X instrument placements in the second half of 2026, and will the expanding installed base translate into the anticipated acceleration of consumables revenue growth to support the high single-digit revenue target for 2027?

Question 2: Will the observed "signs of improvement" in the research and academic markets translate into a meaningful moderation of the mid-to-high single-digit declines in sequencing consumables demand for the second half of 2026, or will cautiousness persist?
Question 3: Can Illumina successfully execute its cost actions and benefit from a favorable product mix shift to achieve the projected operating margin expansion in the second half of 2026, particularly the sequential step-up to approximately 24% in Q3, despite ongoing inflationary pressures?

Earnings Transcript Summary2 rows

2026-07-30 · 2026Q2 Earnings Call

3 Things Management Is Most Focused On	Call Takeaway & Tone	Prior Quarter'S Y/Y Growth By Segment	3 Things Analysts Most Pressed On (And Mgmt Responses)	Revenue Segments
3 Things Management Is Most Focused On1. Sustaining strong performance and clinical market momentum: Management highlighted a "great first half of 2026" and "another strong quarter in Q2," with revenue growing at the fastest rate since the CEO joined, driven by increasing demand in clinical applications. They noted that clinical markets, representing approximately 65% of sequencing consumables revenue, remained the primary growth driver, with broad-based Rest of World clinical growth and strong NovaSeq X placements expanding customer capacity for future consumable growth. 2. Expanding platform value through innovation and multi-omics capabilities: Jacob Thaysen emphasized efforts to "expand the value of our platform through new workflows and multi-omics capabilities." This includes the launch of the whole genome MRD research workflow, the StrataMap Spatial sequencing-based spatial workflow, and sustained proteomics momentum from SomaLogic's SomaScan and SomaSeq offerings. They are also expanding BioInsight with initiatives like the Billion Cell Atlas to advance AI-enabled drug discovery. 3. Achieving long-term strategic and financial targets: Management reiterated their commitment to executing against long-range targets, raising 2026 guidance for revenue growth and profitability. They expressed confidence in the path towards "high single-digit revenue growth in 2027" and reinforced progress towards their 2024 financial targets, citing a "healthy market with significant untapped opportunity."	Call Takeaway & ToneThe overall takeaway of the call was highly positive and confident. Illumina reported a strong Q2 2026 performance, exceeding revenue and EPS expectations, primarily driven by robust demand in clinical markets and continued high NovaSeq X placements. The tone was optimistic, with management expressing strong conviction in the durability of clinical growth, the value of their innovation pipeline (especially multi-omics and AI-enabled drug discovery), and their ability to achieve long-term financial targets. While acknowledging ongoing caution in research markets and inflationary pressures, they conveyed confidence in their operational discipline and strategic execution to mitigate these challenges and sustain growth.	Prior Quarter'S Y/Y Growth By SegmentFor Q1 2026, total revenue was up 4.8% year-over-year (1.2% on an organic basis). Sequencing consumables revenue was up 4% year-over-year (5% Rest of World organic). Clinical sequencing consumable demand, excluding China, grew 20%. Research and applied sequencing consumables, excluding China, declined 12%. Sequencing instruments revenue was up 9% year-over-year (10% Rest of World organic). Sequencing service and other revenue was up 7% year-over-year (5% Rest of World organic). The Microarrays business was down 20% on a Rest of World organic basis.	3 Things Analysts Most Pressed On (And Mgmt Responses)1. Sustainability of NovaSeq X placements and 2027 growth outlook: Analysts questioned the continued high NovaSeq X installs and why the 2027 revenue growth target wasn't higher than "high single-digits" given the current momentum. Management responded that the "growth and the momentum we see in the clinical market will continue for years to come," driven by elevated placements leading to future consumable pull-through. They stated they are "still very committed to delivering on the high single-digit growth" for 2027 by building a strong value proposition. 2. Sequential slowdown in clinical consumables and potential headwind from NovaSeq 6000 decommissioning: Analysts noted a sequential slowdown in clinical consumables growth (from 20% in Q1 to 15% in Q2) and asked about potential "over-earning" on consumables as NovaSeq 6000s are eventually decommissioned. Management clarified that "we continue to see that we have an expansion of volume on the X, and we continue to see quite a number of the 6000s being in action," with some customers even purchasing 6000s, not seeing it as a true headwind. They attributed the slight moderation in clinical growth to "some in and outs in, especially in the Middle East and Latin America," while emphasizing that "mid-teens growth is strong and is still beyond what we started the year with." 3. Q3 guidance step-down, Q4 pacing, and impact of AI-related revenues: Analysts inquired why Q3 guidance showed a step-down from Q2's 8% growth and asked about Q4 pacing, including the impact of an extra week, and the contribution from AI-related revenues like BioInsight. Management explained that Q2 was "very strong" and Q3 typically sees "normal seasonality" as a slightly lower quarter than Q4. They noted that the extra week in Q4 would contribute "maybe half a point or so of revenue" largely from consumables. Regarding AI, they expressed excitement about BioInsight and the Billion Cell Atlas, stating they are "making money already from day one on this, both on top line and bottom line," and see a "significant opportunity over the next period of time."	Revenue SegmentsTotal revenue was $1.16 billion, up 9.5% year-over-year, and 6.5% on an organic basis, with Rest of World organic growth at 8.1%. Sequencing consumables revenue was $775 million, up 5% year-over-year on both a reported and organic Rest of World basis. Clinical markets (ex-China) grew 15%, while research and applied markets (Rest of World) declined 7%. Sequencing instruments revenue was $125 million, up 31% year-over-year on both reported and Rest of World organic basis. Sequencing service and other revenue was $154 million, up 14% on both a reported and Rest of World organic basis. Microarrays and other revenue was $105 million, up 21% reported (including SomaLogic revenue), but declined 4% on a Rest of World organic basis.

2026-04-30 · 2026Q1 Earnings Call

3 Things Management Is Most Focused On	Call Takeaway & Tone	Prior Quarter'S Y/Y Growth By Segment	3 Things Analysts Most Pressed On (And Mgmt Responses)	Revenue Segments
3 Things Management Is Most Focused On1. Disciplined Commercial Execution and Clinical Market Momentum: Management highlighted strong Q1 performance, exceeding guidance, driven by disciplined execution and robust demand in clinical markets. Clinical made up over 65% of sequencing consumables revenue, reflecting continued adoption of sequencing-based diagnostics and more sequencing-intensive applications, which is fueling NovaSeq X placements in clinical settings. 2. Product Innovation and Roadmap Updates: Jacob Thaysen emphasized R&D efforts, including the launch of TruPath for whole genome sequencing, significant customer interest in their spatial transcriptomics offering (on track for launch later this year), and the 18-month roadmap for NovaSeq X, which includes new flow cells (14B and 35B) and improved data quality (Q70). This demonstrates a commitment to expanding the value and capabilities of their platforms. 3. Progress Against Long-Term Strategy and Targets (including NovaSeq X Expansion): Management reiterated confidence in their strategy, noting that the NovaSeq X is central to scaling and expanding customer applications, thereby driving consumables growth. They are raising 2026 guidance and remain on track for their 2027 targets of high single-digit revenue growth, continued margin expansion, and double-digit to teens EPS growth. They also highlighted the successful SomaLogic acquisition and investments in BioInsight and the Billion Cell Atlas.	Call Takeaway & ToneThe overall takeaway of the call was highly positive and confident. Illumina had a strong start to 2026, exceeding Q1 guidance for revenue, margin, and EPS, primarily driven by robust demand in clinical markets and strong NovaSeq X placements. Management expressed confidence in their long-term strategy, emphasizing continuous innovation, NovaSeq X expansion, and disciplined operational execution to drive sustainable growth and margin expansion. While acknowledging ongoing cautiousness in research markets and some near-term inflationary pressures, they conveyed optimism about their ability to mitigate these challenges and achieve their long-range targets, leading to a raised full-year 2026 guidance.	Prior Quarter'S Y/Y Growth By SegmentFor Q4 2025, total revenue was up 5% year-over-year. Sequencing consumables revenue increased 8% year-over-year (11% excluding China). Clinical sequencing consumables, excluding China, grew 20% year-over-year. Sequencing instruments revenue was flat year-over-year (0%). Sequencing service and other revenue was up 4% year-over-year. Specific year-over-year growth percentages for 'Research and applied sequencing consumables (ex China)' and 'Microarrays business' were not explicitly provided in the Q4 2025 search results; however, research and academic demand was noted as subdued in Q4 2025.	3 Things Analysts Most Pressed On (And Mgmt Responses)1. Full-year organic revenue guidance vs. Q1 outperformance: Analysts questioned why the full-year organic revenue guidance wasn't raised more significantly despite the strong Q1 beat, particularly in instruments and clinical. Management (Jacob and Ankur) responded that raising both top and bottom line guidance after only one quarter signals confidence, and the $20 million revenue guidance increase moves them towards the higher end of the previously stated range, representing approximately a 0.5 percentage point increase. 2. NovaSeq X instrument demand, mix, and pricing transition: Analysts pressed on the impressive NovaSeq X placements (over 80 in Q1), asking about the mix between clinical and research, the impact of the NovaSeq 6000 to NovaSeq X pricing transition on consumables, and the outlook for future placements. Management stated that over 60% of placements were clinical and largely incremental, not just conversions. They noted that most research volumes are already on the X, mitigating future price headwinds, and that they were supply-constrained in Q1 due to robust demand, expecting similar placement levels in Q2 with a strong pipeline for the back half. They acknowledged volume discounts for large multi-unit orders but emphasized the primary focus on driving consumables growth. 3. Operating margin progression and Q2 headwinds: Analysts inquired about the Q2 operating margin being lower than expected and the progression throughout the year, given specific headwinds like a higher instrument mix, inflationary pressures (component costs, freight), and a full quarter of SomaLogic. Management (Ankur) explained that mitigating actions are underway, starting in Q2, with their effects expected to become visible from Q3 into Q4, leading to an anticipated ramp-up in operating margin in the second half of the year.	Revenue SegmentsTotal revenue was up 4.8% year-over-year (1.2% on an organic basis). Sequencing consumables revenue was $726 million, up 4% year-over-year, with Rest of World organic growth of 5%. Clinical sequencing consumable demand, excluding China, grew 20%. Research and applied sequencing consumables, excluding China, declined 12%. Sequencing instruments revenue was $118 million, up 9% year-over-year (10% on a Rest of World organic basis). Sequencing service and other revenue was $151 million, up 7% year-over-year (5% on a Rest of World organic basis). The Microarrays business was down 20% on a Rest of World organic basis.

Transcript Tidbits2 rows

2026-07-30

About Expanding Eligible Market	About Competition	About The Broader Industry	Where Things Are Headed	Updates On Theme	Broader Themes Emerging	Bullish-Leaning Quotes (Short)	Bearish-Leaning Quotes (Short)	Hiring
About Expanding Eligible MarketRevenue grew at the fastest rate since Jacob Thaysen joined the company, driven by increasing demand for Illumina's technology as customers expand clinical applications. Clinical markets now represent approximately 65% of sequencing consumables revenue and remained the primary growth driver, with broad-based growth across regions and applications, particularly strong in the U.S.-Canada region. The company expanded its multi-omics portfolio with the launch of StrataMap Spatial, a sequencing-based spatial workflow, and is seeing sustained proteomics momentum from SomaScan and SomaSeq offerings following the SomaLogic acquisition. Illumina is also expanding its BioInsight data and insights offerings to help pharmaceutical customers advance AI-enabled drug discovery, with the Billion Cell Atlas initiative having delivered over 300 million cells and secured six biopharma partners. The whole genome MRD research workflow was also recently launched and is in early access with select customers. Oncology continues to lead application growth, with a shift towards MRD driving momentum, while rare diseases and NIPT screening also show nice growth.	About CompetitionThe company's management expressed confidence in Illumina's value proposition and continued innovation on the NovaSeq X platform, stating that customers see it as the platform to invest in and that this combination is winning in a healthy market.	About The Broader IndustryCustomers in research and academic markets remain cautious due to funding uncertainty, although some signs of improvement were seen late in the quarter, it is too early to call a recovery. Slower growth was observed in the Europe, Middle East, and Latin America region for sequencing consumables in clinical markets, largely due to ongoing near-term dynamics in the Middle East. The mid-throughput instrument market is more muted due to the macro environment. Illumina operates in a healthy market with significant untapped opportunity.	Where Things Are HeadedIllumina is raising its 2026 guidance for revenue growth and profitability, expecting full-year rest-of-the-world organic revenue growth greater than 5%, up from the prior range of 2%-4%. The company anticipates the pace of growth in the second half to remain broadly consistent with the first half, with consumables revenue continuing to grow from a higher installed base, while instrument growth moderates against tougher comparisons. The expanding NovaSeq X installed base is expected to drive further consumables growth beyond 2026 and support a path towards high single-digit revenue growth in 2027. Full-year diluted EPS guidance is raised to $5.30-$5.40, an increase of $0.12 at the midpoint. For Q3 2026, the company expects rest-of-world organic revenue growth of approximately 4.5% and reported revenue of $1.14 billion-$1.16 billion, with non-GAAP EPS of $1.33-$1.38 and non-GAAP operating margin of approximately 24%. Elevated NovaSeq X instrument placements are expected to continue in the second half of the year, with some moderation in year-over-year growth rates. The majority of placements are expected to continue going into the clinical space. The fourth quarter is typically the largest quarter for the year, and there is an extra week in Q4 this year, which could contribute about half a point of revenue, largely from consumables.	Updates On ThemeLife	Broader Themes EmergingAI-enabled drug discovery is emerging as a significant theme, with Illumina expanding its BioInsight data and insights offerings to help pharmaceutical customers advance this area, leveraging sequencing, perturbation tools, compute power, and AI to build high-quality multi-omics data sets and interpretation tools. Inflationary pressures and supply chain costs are also a broader theme, as the company absorbed higher freight and memory costs in the quarter.	Bullish-Leaning Quotes (Short)Revenue grew at the fastest rate since I joined the company. We are raising our 2026 guidance for revenue growth and profitability. Demand for NovaSeq X remained high more than three years after launch, with more than 95 placements in the quarter. Clinical markets, which represent approximately 65% of sequencing consumables revenue, remained our primary growth driver. The momentum we are seeing, especially from our clinical customers, gives us greater confidence as we enter the second half. I'm still very committed to delivering on the high single-digit growth [for 2027]. The momentum we've had here in the first half, I think is going to speak to the opportunity ahead of us.	Bearish-Leaning Quotes (Short)Customers remain cautious as they navigate funding uncertainty. It's too early to call a recovery [in research and academic markets]. We saw slower growth in Europe, Middle East, and Latin America region, largely due to ongoing near-term dynamics in the region. We believe it's still too early to predict the timing of an end market recovery [for research and applied consumables]. We also absorbed higher freight and memory costs in this quarter. Mid throughput is more muted because of the macro environment.	HiringWe recently welcomed Michael Sullivan and Julie Coletti to our management team, adding deep commercial and legal experience as we scale the business. We are equally pleased to welcome David King and Dan Skowronski to our board.

2026-04-30

About Expanding Eligible Market	About Competition	About The Broader Industry	Where Things Are Headed	Updates On Theme	Broader Themes Emerging	Bullish-Leaning Quotes (Short)	Bearish-Leaning Quotes (Short)	Hiring
About Expanding Eligible MarketClinical markets are driving growth, making up over 65% of sequencing consumables revenue, fueled by the expansion of sequencing-based diagnostics and more data-intensive applications. Customers are launching new assays with ongoing reimbursement progress, supporting broader adoption of sequencing in clinical decision-making. Demand for comprehensive genomic profiling and whole genome sequencing is growing, increasing sequencing intensity, with NovaSeq X playing a central role. TruPath, a new whole genome sequencing workflow, is gaining significant interest, especially in rare disease, by simplifying standard of care and consolidating multiple tests. Illumina is on track to launch its spatial transcriptomics offering later this year, which has shown high engagement from early access users for challenging sample types. The NovaSeq X roadmap includes new 14B and 35B flow cells, staggered runs, and Q70 performance improvements, offering more flexibility, throughput, and workflow efficiency. BioInsight and the Billion Cell Atlas program are accelerating discovery and supporting AI-driven models for drug discovery, with growing partner interest. Clinical NovaSeq X placements are largely incremental, rather than conversions, immediately driving top-line growth.	About CompetitionIllumina does not see a substantial change in the competitive environment and looks forward to competing when new offerings reach the market. The company acknowledges competitive pricing discussions around cost per genome (e.g., $150 price point) but is not ready to discuss 35B flow cell pricing yet, focusing on elasticity and volume growth. Illumina views 10x Genomics' spatial launch positively, believing it drives overall interest in spatial biology, and sees room for multiple players due to different technologies and customer segments.	About The Broader IndustryThe clinical market shows sustained strength, while research and academic markets remain cautious due to funding uncertainty. There is alignment in Washington D.C. regarding NIH funding commitment, which is expected to pick up during the year, though translation into actual spending on tools and consumables may take time. The industry is experiencing near-term inflationary pressures related to freight costs and electronic components. The NovaSeq X transition for research customers is largely complete (over 90% volume), meaning less price headwind when that market recovers.	Where Things Are HeadedIllumina is raising its 2026 revenue guidance to $4.52 billion to $4.62 billion, operating margin expectations to 23.4% to 23.6%, and non-GAAP diluted EPS to $5.15 to $5.30, reflecting Q1 outperformance and business strength. The company remains on track for its 2027 targets of high single-digit revenue growth, continued margin expansion, and double-digit to teens EPS growth. Clinical market momentum is expected to continue into the coming years, with NovaSeq X placements driving consumables revenue approximately six months after installation. NovaSeq X placements are expected to be similar to Q1 levels (80+ units) in Q2, with a robust pipeline for the back half of the year, leading to full-year placements "reasonably above" the initial range. Investments are being made to scale NovaSeq X supply through Q2 and Q3 due to strong demand. Mitigating actions for inflationary pressures are expected to become visible in Q3 and Q4, leading to margin improvement in the second half of the year. The majority of clinical volumes (80% to 85%) are expected to transition to NovaSeq X by the end of 2026. Improvement in the research market due to easing funding uncertainties is considered an upside to the current guidance.	Updates On ThemeDiagnostics	Broader Themes EmergingArtificial Intelligence (AI) is mentioned in the context of BioInsight and the Billion Cell Atlas for accelerating discovery and supporting AI-driven models for drug discovery. Inflationary Pressures are noted as impacting freight costs and electronic components, requiring mitigating actions. Government Funding Dynamics, specifically NIH funding, are discussed regarding their impact on research spending.	Bullish-Leaning Quotes (Short)We are off to a great start in 2026 with Q1 revenue, margin and EPS all coming in above our guidance range. Over 80 NovaSeq X placements in the quarter, approximately 20 more than Q1 '25, with year-over-year placements growth in both clinical and nonclinical markets. Clinical made up more than 65% of our sequencing consumables revenue in the quarter, driven by both the expansion of sequencing-based diagnostics and the increased use of more data-intensive applications. We see a long runway for continued growth in our clinical business. We are raising our 2026 guidance to reflect the Q1 outperformance. We also remain on track toward our 2027 targets and the investments we are making in R&D and product innovation position us to deliver high single-digit revenue growth, continued margin expansion and double-digit to teens EPS growth for years to come. In fact, during Q1, we were supply constrained on the number of NovaSeq X units that were placed as the demand continues to remain very robust. I think our placements of instruments shows that there's no freezing of any market that we are participating in at this point. We are around above $1.3 million of pull-through on the Xs. And we think that, that will continue to be at that level, if not above. We don't -- we're not seeing any signs of potential deceleration per se in that market. There's good momentum there.	Bearish-Leaning Quotes (Short)In research and academic markets, demand remains cautious as customers navigate funding uncertainty. Sequencing consumables in research and applied declined 12% ex China, reflecting continued uncertainty in the funding environment during the quarter. Microarrays business was down 20% on a Rest of World organic basis, largely due to specific large customers in direct-to-consumer segment. Our guide assumes operating margins of approximately 22%, reflecting higher mix of instruments revenue and related investments, near-term inflationary pressures related to freight costs and higher cost of electronic components and a full quarter of SomaLogic as well. One thing is to have released grants, but the other thing is to have it all translated into spending the money on actually tools and consumables. And there are definitely some cautiousness with our customers before they've truly understand how those grants -- who are getting the grants and how many grants you're getting, there will be some cautiousness in that space for a little while.	HiringNon-GAAP operating expenses were up 3% year-over-year, largely reflecting the addition of the SomaLogic team, indicating workforce expansion through acquisition.